Cambridge Cognition Holdings plc

Kintsugi CEO Grace Chang is hopeful that the company’s voice biomarkers technology for detecting depression and anxiety from short clips of free speech will receive the nod of approval from US regulat

Decentralized clinical trials (DCT), or sometimes “virtual trials,” were gaining momentum prior to the COVID-19 pandemic. However, when in-person clinical sites were closed due to the pandemic, many c

Rising Leaders Home Central nervous system disorders represent a huge and growing unmet health need, yet drug development has stalled for some conditions and has not got off the ground at all for oth

Recently spun out from UK-based Cambridge Cognition Holdings plc with 15-months’ worth of working seed capital, CNS-focused Monument Therapeutics is now working to put two repurposed and reformula